The historical rank and industry rank for NUTEX Investments's Gross Margin % or its related term are showing as below:
During the past 13 years, the highestGross Margin % of NUTEX Investments was 1.83%. The lowest was 1.83%. And the median was 1.83%.
BUD:NUTEX's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.46 * Ranked among companies with meaningful Gross Margin % only.
NUTEX Investments had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for NUTEX Investments was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
NUTEX Investments had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
NUTEX Investments Gross Margin % Related Terms
NUTEX Investments Gross Margin % Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Gross Margin % distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
NUTEX Investments (BUD:NUTEX) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on NUTEX Investments and its competitors. Over the past decade, NUTEX Investments' Gross Margin % has ranged from 1.83 to 1.83. According to the industry distribution chart, NUTEX Investments ranks #999999 out of 937 companies in the Drug Manufacturers industry.
Is NUTEX Investments' Gross Margin % too high?
NUTEX Investments' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 1.83. Based on the distribution chart, NUTEX Investments ranks #999999 out of 937 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #999999 out of 937 companies for Gross Margin %. This places NUTEX Investments in the lower half of its industry. The industry median Gross Margin % is 48.46. Historically, NUTEX Investments' own Gross Margin % has ranged from 1.83 to 1.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current Gross Margin % is 0.00%. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Gross Margin %: 0.00%
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
